New

Novo Nordisk Just Pulled Off Something Nobody Saw Coming

Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again.

A new launch could reshape obesity treatment

Novo has a new weapon in its obesity portfolio with the once-daily Wegovy tablet, which is the first oral GLP-1 medication approved in the U.S. for weight loss. This comes at a time when competition is heating up and prices are going up. This pill is different from the injections that have been the most common in the GLP-1 area because it wants to make it easier for millions of people to use the medicine.

Dave Moore, executive vice president of U.S. operations at Novo Nordisk, said:

The question now isn't just whether this new format works. It's also about whether it can make things easier for more people, protect Novo's market share, and keep the company ahead of Eli Lilly's upcoming competitor. When the pill comes out in stores in the U.S. in early January, investors will be watching what happens.

What the pill launch could add to Novo Nordisk revenue

Novo's business in obesity is already huge. The business said that in the first nine months of 2025, it made DKK 59.9 billion from obesity care sales, which is a 41% increase at constant exchange rates. This growth rate helps explain why the market is so interested in every small improvement in GLP-1s.

But there are issues to keep in mind as well. Novo cut their forecast for 2025 because competition and pricing pressure were getting worse. This is a warning that even in the "golden era" of the business, there can always be problems.

More Health Care:

That's the background for the latest headline: a new product that the FDA has approved that could bring in more patients and change the way prices are calculated.

Novo Nordisk’s Wegovy pill lands FDA approval

The FDA approved the Wegovy pill (oral semaglutide 25 mg) for individuals who are obese or overweight and have at least one weight-related disorder, according to a Monday statement. They can take it once a day to help them manage their weight.

It's the first oral GLP-1 licensed in the U.S. just for weight loss, which is a big plus in a market where many patients don't want to get shots.

Novo also talked about a second FDA-approved use: lowering the risk of serious cardiovascular events (such as heart attack or stroke) in individuals who are overweight or obese and already have cardiovascular disease.

Oral weight-loss medication could unlock new patients

The OASIS 4 phase 3 trial in individuals who are overweight or obese (but not diabetic) is what led to the approval. In one study, patients who took the tablet lost an average of 16.6% of their body weight, whereas those who took a placebo lost only 2.7%. In another study, the difference was 13.6% versus 2.4%.

Side effects are similar to those of the GLP-1 class, with nausea, diarrhea, and vomiting being common in trials, which is the same as what has been found with injectable Wegovy.

One real-world problem with the medication is how often you have to take it. It has to be taken on an empty stomach, which could affect how well people follow the instructions, even though the medication gets rid of the need for injections.

Healthcare pricing pressure rises as coverage expands

Novo plans to launch in the U.S. in early January 2026. The company states that the starter dose (1.5 mg) will be available for $149 per month with savings offers, and that it has a lot of supplies on hand and is making more in the U.S.

Investors should pay close attention to the price messages: As media and political criticism have grown, Novo has increasingly focused on headlines about how affordable it is.

Financial impact of drugs is equal to more volume, tighter margins

This is the tradeoff that investors will be watching.

A pill could lead to more prescriptions by making things easier, but efforts to make drugs more widely available and payers' power can lower prices. As talks between government and private insurance continue, it may be more beneficial to focus on volume growth than premium price.

This means that the Wegovy pill could speed up sales while pricing power is being explored.

Eli Lilly rivalry fuels drug competition in GLP-1s

Novo is the first company to get FDA approval for an oral obesity drug, but not the last. Eli Lilly's oral obesity contender orforglipron is still a big threat, and how well it does will affect how long Novo's "pill advantage" lasts.

Over the next few years, oral weight-loss alternatives could become a big part of the market. This is why being the first to market is so important. If patients and doctors like pills, the competitive landscape and product mix might change swiftly.

What’s next in obesity treatment

Keep an eye on:

January 2026 rollout: how quickly the pill scales and whether demand adds to or replaces injections
Coverage and rebates: do payers see the pill as a less expensive way to get on board, or do they tighten controls?
Timing and positioning from Eli Lilly and other competitors are important.
Pill dosage is a real-world issue. It must be taken on an empty stomach, which may affect adherence even if it removes the injection barrier.

Back to Listing

credit: